美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。要求该公司暂停Elevidys临床试验。研究的受试对象可能会面临不合理的风险。该公司拒绝自愿停止发货Elevidys。

Group 1 - The FDA has requested Sarepta Therapeutics Inc. to suspend the distribution of Elevidys [1] - The company is also required to pause clinical trials for Elevidys due to potential unreasonable risks to participants [1] - Sarepta Therapeutics Inc. has refused to voluntarily stop the shipment of Elevidys [1]